Skip to content

    ImmunityBio (IBRX) stock price & financials

    View IBRX earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+244.0% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $6.11M
    $7.55M
    $16.52M
    $26.43M
    $32.06M
    +425.1%
    $38.28M
    +407.0%
    $44.21M
    +167.6%
    $51.24M
    +93.9%
    Strengthening
    Operating Profit
    -$80.25M
    -$69.40M
    -$64.43M
    -$71.28M
    -$55.63M
    +30.7%
    -$64.68M
    +6.8%
    -$69.79M
    -8.3%
    -$61.70M
    +13.5%
    Strengthening
    Net Profit
    -$85.73M
    -$59.16M
    -$129.65M
    -$92.56M
    -$67.25M
    +21.6%
    -$61.94M
    -4.7%
    -$632.78M
    -388.1%
    -$230.38M
    -148.9%
    Weakening
    EPS
    $-0.12
    $-0.15
    $-0.10
    $-0.07
    +41.7%
    $-0.62
    -313.3%
    $-0.22
    -120.0%
    Weakening
    Other Income
    -$5.50M
    $10.22M
    -$65.47M
    -$21.02M
    -$11.68M
    -112.4%
    $2.59M
    -74.7%
    -$563.00M
    -759.9%
    -$168.69M
    -702.5%
    Weakening
    Interest
    $29.32M
    $26.02M
    $15.31M
    $15.47M
    $15.26M
    -48.0%
    $14.84M
    -43.0%
    Weakening
    Depreciation
    Profit before Tax
    -$85.75M
    -$59.18M
    -$129.90M
    -$92.31M
    -$67.31M
    +21.5%
    -$62.09M
    -4.9%
    -$632.79M
    -387.1%
    -$230.39M
    -149.6%
    Weakening
    MarginsOPM
    -1314.3%
    -919.0%
    -390.1%
    -269.8%
    -173.5%
    +86.8%
    -168.9%
    +81.6%
    -157.9%
    +59.5%
    -120.4%
    +55.4%
    Strengthening
    Tax
    0.0%
    0.0%
    0.2%
    -0.3%
    0.1%
    0.2%
    0.0%
    -100.0%
    0.0%
    +100.0%
    Stable
    ReturnsROIC
    1.8%
    1.2%
    2.7%
    1.9%
    1.4%
    -21.6%
    1.3%
    +4.7%
    13.0%
    +388.1%
    4.7%
    +148.9%
    Strengthening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$16.82M$75.80M$34.91M$181.10M$104.64M$265.45M$143.43M$88.33M$75.67M
    Short-Term Investments$61.15M$136.01M$2.54M$1.01M$6.38M$154.48M$281.70M
    Total Current Assets$88.77M$55.76M$111.71M$334.35M$140.58M$294.08M$184.59M$314.88M$438.98M
    Net PP&E$76.89M$72.23M$90.68M$119.17M$189.45M$182.63M$170.46M$147.27M$145.49M
    Goodwill$910.0K$910.0K
    Intangibles$565.0K$0$1.46M$1.42M$20.00M$17.09M$14.53M$12.99M
    Total Assets$181.95M$143.12M$221.38M$468.91M$362.36M$504.45M$382.93M$501.90M$628.50M
    LiabilitiesTotal Current Liabilities$27.26M$11.56M$68.13M$369.00M$500.86M$58.28M$54.94M$61.75M$76.73M
    Short-Term Debt$1.25M$1.75M
    Long-Term Debt
    Long-Term Leases$0$10.88M$16.18M$37.07M$47.95M$39.94M$34.82M$33.45M$31.20M
    Total Liabilities$35.94M$22.44M$339.87M$712.82M$812.18M$1.09B$871.06M$1.00B$1.67B
    EquityCommon Stock & APIC$8.0K$10.0K$38.0K$40.0K$42.0K$67.0K$85.0K$101.0K$105.0K
    Retained Earnings-$594.98M-$662.19M-$1.62B-$1.96B-$2.38B-$2.96B-$3.38B-$3.73B-$4.59B
    Total Equity$146.01M$120.68M-$119.81M-$242.17M-$447.33M-$586.99M-$489.10M-$500.47M-$1.05B
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$63.38M-$152.11M-$171.72M-$274.42M-$337.51M-$366.76M-$391.24M-$304.94M-$281.14M
    Cash from Investing$57.10M$18.55M-$19.81M-$84.89M$27.30M-$30.47M-$12.25M-$149.80M-$276.91M
    Cash from Financing-$771.0K$114.28M$150.68M$505.44M$233.61M$558.34M$281.63M$400.24M$496.78M
    SummaryCapital Expenditure-$13.10M-$4.29M-$1.67M-$33.56M-$78.16M-$30.58M-$6.89M-$3.85M-$6.94M
    Free Cash Flow-$76.48M-$156.40M-$173.39M-$307.98M-$415.67M-$397.34M-$398.12M-$308.78M-$288.07M
    FCF Margin-162729.8%-7102.5%-28660.0%-32974.5%-173196.3%-63881.2%-2700.1%-272.6%-173.8%

    Ratios